Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
15 sept. 2020 07h00 HE
|
Novavax, Inc.
Serum Institute of India to manufacture ~1 billion doses of NVX-CoV2373 in 2021Increases global manufacturing capacity for NVX-CoV2373 to over 2 billion annualized doses when at full capacity in...
Novavax to Participate in Upcoming Investor Conferences
10 sept. 2020 07h00 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine
02 sept. 2020 17h14 HE
|
Novavax, Inc.
GAITHERSBURG, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine
31 août 2020 08h55 HE
|
Novavax, Inc.
• Canadian government to purchase up to 76 million doses of NVX-CoV2373 GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company...
Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine
24 août 2020 09h00 HE
|
Novavax, Inc.
Primary objectives expand evaluation of immunogenicity and safetySecondary objectives include preliminary efficacy assessmentTrial to enroll up to 1,500 volunteers in United States and Australia, with...
Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa
17 août 2020 02h30 HE
|
Novavax, Inc.
Phase 2b clinical trial in collaboration with Professor Shabir Madhi and Wits UniversityBill & Melinda Gates Foundation providing $15 million grant toward trialMature trial infrastructure along...
Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate
14 août 2020 01h07 HE
|
Novavax, Inc.
UK government to purchase 60 million doses of NVX-CoV2373Novavax to partner with FUJIFILM Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UKNovavax and UK government to...
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
13 août 2020 08h30 HE
|
Novavax, Inc.
SK bioscience to manufacture antigen component of NVX-CoV2373Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373Novavax, SK bioscience and Republic of Korea...
Novavax Reports Second Quarter 2020 Financial and Operational Results
10 août 2020 16h02 HE
|
Novavax, Inc.
Announced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373Secured $2 billion in funding for global coronavirus vaccine program through CEPI, DoD, and OWSExpanded large scale global...
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
07 août 2020 05h26 HE
|
Novavax, Inc.
Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in JapanMatrix-M adjuvant to be supplied from NovavaxGovernment of Japan will provide funding to...